Evaluating Volume Changes in the Substantia Nigra Pars Compacta (SNc) in Parkinson’s Disease (PD) in a Study-Specific Magnetic Resonance Imaging (MRI) Template
Objective: To characterize the topography of SNc involvement in PD patients using neuromelanin (NM)-sensitive MRI (NM-MRI). Background: PD is characterized by the progressive loss of…“Brain-first” vs. “body-first” Parkinson’s disease is determined by RBD-status – a multi-modality imaging study
Objective: In a multi-modality imaging study, we test the hypothesis that Parkinson’s disease (PD) can be divided into two strikingly distinct phenotypes: (1) PD patients,…Functional Biomarkers of Parkinson’s Disease: Changes in Brain-Wide Network Connectivity in Default Mode and Fronto-Parietal Control Networks
Objective: Parkinson’s disease (PD) is a neurological disorder with no reliable biomarkers. We aimed to investigate naturalistic paradigms as functional biomarkers that distinguish between PD…Genotype influences circuit compensation in Parkinson’s disease
Objective: This study investigates differences in brain network organization in patients with Parkinson’s disease (PD) with genetic risk factors relative to sporadic PD patients and…Challenges in Parkinson’s Disease Diagnosis in a Patient with Ipsilateral Hemimelia
Objective: Our main objective is to demonstrate the challenges involved in the diagnosis of parkinsonism in a patient with transverse failure of formation of the…Stability and reliability of objective measures of speech in Parkinson’s Disease over 12 months
Objective: To describe the stability and reliability of acoustic measures of speech in Parkinson’s Disease (PD) at 3 and 12 months. Background: Speech biomarkers hold…Safinamide improves motor symptoms severity and daily living in Parkinson’s Disease (PD) patients
Objective: To evaluate the clinical effects of safinamide, administered as add-on therapy to levodopa in fluctuating PD patients, on symptoms severity and daily living. Background:…Design, characterization and In vivo evaluation of intranasal delivery of levodopa loaded microspere for Parkinsonism
Objective: Levodopa is the drug of choice in the treatment of Parkinson's disease but it exhibits low oral bioavailability and very low brain uptake. The…Multi-kinase Abelson (c-Abl) and Discoidin Domain Receptors (DDR1/2) inhibitors, Nilotinib, alters CSF soluble TREM2 (sTREM2) in individuals with Parkinson’s Disease
Objective: Our objective was to examine the effects of broad-based tyrosine kinase inhibition in cerebrospinal fluid biomarkers. Background: Nilotinib is a broad-based tyrosine kinase inhibitor…INTREPID: A 2-Year Follow-Up of a Prospective, Double Blinded, Multi-Center Randomized Controlled Trial Evaluating Deep Brain Stimulation with a New Multiple Source, Constant-Current Rechargeable System for Treatment of Parkinson’s Disease
Objective: The objective of the INTREPID clinical trial assessed improvement in motor function and quality of life in patients with advanced, levodopa responsive Parkinson's disease…
- « Previous Page
- 1
- …
- 149
- 150
- 151
- 152
- 153
- …
- 405
- Next Page »